AGC Biologics S.p.A. is the Italian subsidiary of AGC Biologics, a global contract development and manufacturing organization (CDMO) owned by AGC Inc. The company serves biopharmaceutical developers by providing development and GMP manufacturing services for advanced therapies.
Based in the Milan area, AGC Biologics S.p.A. specializes in cell and gene therapy production, including lentiviral vector manufacturing and ex vivo genetically modified cell processing for clinical and commercial supply. Its capabilities include process and analytical development, technology transfer, scale-up, quality control, and regulatory support for U.S. and EU markets. The site operates within AGC Biologics’ international network across Europe, North America, and Asia.
Official website: agcbio.com
chemXplore tracks active investment projects involving AGC Biologics S.p.A., across sectors such as Basic Chemicals, Biobased & Circular, and Polymers.
AGC Biologics S.p.A.'s role is mapped on each — as Owner, Operator, and Developer.
To provide comprehensive coverage, we aggregate data and news under the name AGC Biologics S.p.A., encompassing the following company names, divisions, and related entities:
AGC Biologics, AGC Biologics, Inc., and AGC Bio.
This list encompasses current and former names, alternate names, and key divisions associated with AGC Biologics S.p.A., ensuring you can easily find all relevant information under a single, unified profile.
